Thierry Damerval was appointed President and CEO of the French National Research Agency (ANR) by presidential decree on December 8, 2017, having been proposed for the role by the Minister for Higher Education, Research and Innovation.
Having joined Inserm in December 2007 as Deputy Chief Executive Officer for Strategy, Thierry Damerval became Deputy Director General in 2011, alongside André Syrota and subsequently Yves Lévy.
Over a ten-year period, Thierry Damerval supported the organization’s strategy through some of Inserm’s key milestones in a context of a rapidly changing research landscape: creation of the Aviesan Alliance, coordinated by Inserm in 2009; evaluation of Inserm by an international committee in 2008 and 2015, definition of the 2010-2015 and 2016-2020, strategic plans, as well as the associated performance agreements; participation of Inserm in the French Investissements d’avenir [Investments for the Future] program since 2010.
Thierry Damerval also represented Inserm on numerous bodies essential to extending the organization’s reach, both nationally, in the context of the site policy, and on a European level, within the EMRC (European Medical Research Council), for example, or as France’s representative in the States Representatives Group (SRG) of the European Union’s IMI (Innovative Medicines Initiative).
Thierry Damerval helped support Inserm’s new structure in the form of theme-based institutes, enabling the organization to be reactive in its response to major research challenges in key scientific areas. He worked closely with major bodies and, in particular, the chairs of Inserm’s various scientific advisory boards.
He also supported the implementation of structural changes within the organization, coordinating the actions of departments and regional offices since 2011. Finally, he oversaw the reinforcement of social dialog, either within the context of the CHSCT (Health, Safety and Working Conditions Committee), which he chaired, or in liaison with Inserm’s Social support and mutual assistance committee (CAES).
A new version of the Inserm website is now online. Designed and created by Inserm and the W* agency, the site has been rethought, not only in terms of graphics, but also from an ergonomic, technical, and editorial perspective. Objective: to consolidate ...
To become the most advanced and competitive genomics research and healthcare system in the world: such was the ambition declared by Inserm, and its partners Aviesan and Genomics England Ltd, during the UK-France Summit on January 18, 2018. An agreement was signed ...